2. Academic Validation
  3. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells

  • Nature. 2014 Mar 27;507(7493):508-12. doi: 10.1038/nature12998.
Magdalena Paolino 1,  Axel Choidas 2,  Stephanie Wallner 3,  Blanka Pranjic 1,  Iris Uribesalgo 1,  Stefanie Loeser 1,  Amanda M Jamieson 4,  Wallace Y Langdon 5,  Fumiyo Ikeda 1,  Juan Pablo Fededa 1,  Shane J Cronin 1,  Roberto Nitsch 1,  Carsten Schultz-Fademrecht 2,  Jan Eickhoff 2,  Sascha Menninger 2,  Anke Unger 2,  Robert Torka 6,  Thomas Gruber 3,  Reinhard Hinterleitner 3,  Gottfried Baier 3,  Dominik Wolf 7,  Axel Ullrich 6,  Bert M Klebl 2,  Josef M Penninger 1
Affiliations

Affiliations

  • 1 IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, 1030 Vienna, Austria.
  • 2 Lead Discovery Center GmbH, D-44227 Dortmund, Germany.
  • 3 Medical University Innsbruck, 6020 Innsbruck, Austria.
  • 4 Department of Microbiology and Immunology, Brown University, Providence, Rhode Island 02912, USA.
  • 5 School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia 6009, Perth, Australia.
  • 6 Max-Planck, Institute for Biochemistry, Department of Molecular Biology, D-82152 Martinsried, Germany.
  • 7 1] Medical University Innsbruck, 6020 Innsbruck, Austria [2] Internal Medicine III, University Hospital Bonn, 53127 Bonn, Germany.
PMID: 24553136 DOI: 10.1038/nature12998
Abstract

Tumour metastasis is the primary cause of mortality in Cancer patients and remains the key challenge for Cancer therapy. New therapeutic approaches to block inhibitory pathways of the immune system have renewed hopes for the utility of such therapies. Here we show that genetic deletion of the E3 ubiquitin Ligase Cbl-b (casitas B-lineage lymphoma-b) or targeted inactivation of its E3 Ligase activity licenses natural killer (NK) cells to spontaneously reject metastatic tumours. The TAM tyrosine kinase receptors TYRO3, Axl and Mer (also known as Mertk) were identified as ubiquitylation substrates for Cbl-b. Treatment of wild-type NK cells with a newly developed small molecule TAM kinase inhibitor conferred therapeutic potential, efficiently enhancing anti-metastatic NK cell activity in vivo. Oral or intraperitoneal administration using this TAM inhibitor markedly reduced murine mammary Cancer and melanoma metastases dependent on NK cells. We further report that the anticoagulant warfarin exerts anti-metastatic activity in mice via Cbl-b/TAM receptors in NK cells, providing a molecular explanation for a 50-year-old puzzle in Cancer biology. This novel TAM/Cbl-b inhibitory pathway shows that it might be possible to develop a 'pill' that awakens the innate immune system to kill Cancer metastases.

Figures
Products